Another antibiotic maker bites the dust, as Tetraphase is swallowed for cheap

Some four years after it reported its first batch of pivotal trial data, Tetraphase finally secured FDA approval for its lead antibiotic, eravacycline, for complicated intra-abdominal infections in 2018. But like many of its peers, merely securing approval was only the first hurdle.